$0.00
$0.60
bear $0.00
base $0.15
bull $0.60
margin of safety $0.10
market price* $1.89
Business condition attached to the margin of safety
FDA accepts a resubmitted GTx-104 application and the contract manufacturer's cited manufacturing deficiencies are confirmed remediated, with cash still above roughly $10 million.
Grace Therapeutics (formerly Acasti Pharma) is a pre-revenue specialty pharmaceutical company. Its lead product, GTx-104, is an intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage. The company has no product sales and has lost money every year since inception, with an accumulated deficit of $228.5 million at March 31, 2026. In April 2026 the FDA issued a Complete Response Letter on the GTx-104 application, citing manufacturing deficiencies at the contract manufacturer (current Good Manufacturing Practice findings) and other non-clinical issues. The company has paused commercialization preparations while it remediates and plans a resubmission. Approval, launch and sales are therefore not yet secured, and we do not credit any of them in any case. Earnings power: on an owner-earnings basis (operating cash flow less stock compensation and capital spending, which is negligible) the company consumed about $0.59 per share in fiscal 2026, versus $1.29 in 2025, $1.39 in 2024, $2.38 in 2023 and $3.02 in 2022 (share counts restated for the 2023 reverse split). Losses per share have narrowed, but they are still losses; there is no earnings level to capitalize. Cash was $17.0 million at March 31, 2026 and $13.8 million at June 30, 2026, about $0.80 per share, against annual cash burn of roughly $9 to 15 million. Shares outstanding have grown from about 6 million to about 17 million post-split through repeated equity raises, and management states it plans to raise more capital. Bear case ($0): the resubmission is delayed or fails on the manufacturing findings, the cash is spent on remediation and overhead, and new financing dilutes existing holders so heavily that nothing is left for today's shares. The auditors flagged liquidity as a critical audit matter, though management states cash is sufficient for at least twelve months. Base case ($0.15): the company spends most of its remaining cash pursuing the resubmission, and the value to current shareholders is what is left of the cash after remediation costs and expected dilution. No revenue from GTx-104 is included because approval has not happened. Bull case ($0.60): remediation is completed efficiently, cash burn stays near the recent lower run rate, and roughly 70% of current cash is preserved for current holders. Even here we give no value to a potential launch, since nothing about approval or commercial terms is yet secured. If the drug is approved, the true value could be well above this figure, which is the reason for the business condition below rather than a price that can be defended today. What would make this wrong: an approval of the resubmitted application on a short timeline would make all three cases too low. Conversely, another financing at a discount would make them too high. The margin-of-safety price is set very low, given the tiny market capitalization, the dependence on a single product and repeated dilution, and it assumes the FDA accepts the resubmission and the manufacturing findings are confirmed cleared.